2020 - Integration of mechanical conditioning into a high throughput contractility assay for cardiac safety assessment
FLEXcyte 96 Publication in the Journal of Pharmacological and Toxicological Methods (2020)
Gossmann M., Linder P., Thomas U., Juhasz K., Lemme M., George M., Fertig N., Dragicevic E., Stoelzle-Feix S.
Journal of Pharmacological and Toxicological Methods (2020) doi: 10.1016/j.vascn.2020.106892
Despite increasing acceptance of human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) in safety pharmacology, controversy remains about the physiological relevance of existing in vitro models for their mechanical testing. We hypothesize that existing signs of immaturity of the cell models result from an improper mechanical environment. With the presented study, we aimed at validating the newly developed FLEXcyte 96 technology with respect to physiological responses of hiPSC-CMs to pharmacological compounds with known inotropic and/or cardiotoxic effects.